Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial on Abiraterone Acetate Plus Prednisone
2019 Genitourinary Cancers Symposium
Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses final phase III findings on men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer who were treated with abiraterone acetate plus prednisone added to androgen-deprivation therapy (Abstract 141).
Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses study findings on the efficacy and safety of darolutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 140).
Jason A. Efstathiou, MD, DPhil, of Massachusetts General Hospital, discusses the debate over treating muscle-invasive bladder cancer with radical cystectomy vs trimodality therapy.
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence as well as genomic data that could help pinpoint individual tumor biology.
Stefanie C. Fischer, MD, of Manchester Cancer Research Centre and The Christie NHS Foundation Trust, discusses an international retrospective analysis of the rare clinical scenario of men relapsing after adjuvant treatment with bleomycin/etoposide/cisplatin for clinical stage I nonseminoma (Abstract 510).
Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials on metastatic castration-resistant prostate cancer (Abstract 143).